{"id":2742,"date":"2019-10-07T22:38:01","date_gmt":"2019-10-07T20:38:01","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2742"},"modified":"2025-03-24T08:05:29","modified_gmt":"2025-03-24T07:05:29","slug":"synovial-inflammation-and-bone-metabolism","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/translational-medicine-area\/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program\/synovial-inflammation-and-bone-metabolism\/","title":{"rendered":"Synovial inflammation and bone metabolism"},"content":{"rendered":"\n

\n\t\tSynovial inflammation and bone metabolism\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tArthritis is the inflammation of one or more joints, and involves cartilage degradation. This disease has a variety of origins, and the Synovial Inflammation and Bone Metabolism group studies both the causes and treatments associated with this condition, and the possible complications and relationships with other diseases such as osteoporosis.
\nSimultaneously, the group has an area of study on systemic autoimmune diseases, which include a wide variety of diseases caused by a reaction of the patient’s own immune system to the body.\n

322<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"the_horse_its_treatment_in_health_and_disease_with_a_complete_guide_to_breeding_training_and_management_1906_14585649459\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tGiant-cell arthritis
\nInfectious arthritis
\nPsoriatic arthritis
\nRheumatoid arthritis
\nAnkylosing spondylitis
\nSystemic autoimmune diseases
\nOsteoporosis\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Herrero Morant,A; Martin Varillas,JL; Castaneda,S; Maiz,O; Sanchez,J; Ortego,N;Raya,E et al, Biologic therapy in refractory neurobehcet’s disease: a multicentre study of 41 patients and literature review<\/strong>, Rheumatology (Oxford), 2022;61(11):4427-4436, doi:10.1093\/rheumatology\/keac097<\/p>\n

Morales Ivorra,I; Narv\u00e1ez,J; G\u00f3mez Vaquero,C; Moragues,C; Nolla,JM; Narv\u00e1ez,JA; Mar\u00edn L\u00f3pez,MA, Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique<\/strong>., RMD Open, 2022;8(2):doi:10.1136\/rmdopen-2022-002458<\/p>\n

Morales Ivorra,I; Narvaez,J;Gomez Vaquero,C; Moragues,C; Nolla,JM; Narvaez,JA; Marin Lopez,MA, A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis<\/strong>, RMD Open, 2022; 8(2): doi:10.1136\/rmdopen-2022-002615<\/p>\n

Michelena,X; Lopez Medina,C; Erra,A; Juanola,X; Font Ugalde,P; Collantes,E; Marzo Ortega,H, Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry<\/strong>, RMD Open, 2022;8(2):doi:10.1136\/rmdopen-2022-002513<\/p>\n

Llop,M; Moreno,M; Navarro Compan,V; Juanola,X; de Miguel,E; Almodovar,R; Quintana,EC et al, Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO<\/strong>, Arthritis Res Ther, 2022;24(1):30-30, doi:10.1186\/s13075-021-02695-5<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

21MAR007. Design of an integrative patients stratification approach for the systemic sclerosis management<\/strong>. Fundaci\u00f3 La Marat\u00f3 de TV3. Budget: 143583. 2021-2024. PI: Narv\u00e1ez Garc\u00eda, Javier.<\/p>\n

18ACL007. ESTUDIO DE FASE 4 ABIERTO, RANDOMIZADO CONTROLADO QUE COMPARAR LA EFICACIA DE LA INTRODUCCI\u00d3N DE ADALIMUMBAB Y EL ESCALADO DE DOSIS DE METOTREXATO EN PACIENTES CON ARTRITIS PSIRI\u00c1SICA (CONTROL)<\/strong>. Budget: 47545. 2018- . PI: Ruiz Mart\u00edn, Jos\u00e9 Miguel.<\/p>\n

21PRC004. REGISPON-3: SEGUIMIENTO DEL REGISTRO ESPA\u00d1OL DE ESPONDILOARTRITIS. ASPECTOS CL\u00cdNICOS, TERAP\u00c9UTICOS Y MOLECULARES<\/strong>. Budget: 30700. 2021- . PI: Juanola Roura, Xavier.<\/p>\n

17FIS031. Red de Investigaci\u00f3n en Inflamaci\u00f3n y Enfermedades Reum\u00e1ticas (RIER)<\/strong>. Budget: 16500. 2017-2022. PI: Narv\u00e1ez Garc\u00eda, Javier.<\/p>\n

2022-018-1. PAUTAS DE TRATAMIENTO CON UPADACITINIB, CONSECUCI\u00d3N DE LOS OBJETIVOS TERAP\u00c9UTICOS Y MANTENIMIENTO DE LA RESPUESTA EN PACIENTES CON ARTRITIS REUMATOIDE DE MODERADA A GRAVE EN LA PR\u00c1CTICA REAL (UPHOLD)<\/strong>. AbbVie Spain, S.L.U. Budget: 9100. 2021- . PI: Ruiz Mart\u00edn, Jos\u00e9 Miguel.<\/p>\n\t\t\t\t\"Francisco-Javier-Narvaez-Garcia\"\n

\n\t\tNarv\u00e1ez Garcia, Francisco Javier\n\t<\/h4>\n

\n\t\t\n\t\tfjnarvaez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Francisco-Javier-Narvaez-Garcia\"\n

\n\t\tNarv\u00e1ez Garcia, Francisco Javier\n\t<\/h4>\n

\n\t\t\n\t\tfjnarvaez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tG\u00f3mez Vaquero, Carmen\n\t<\/h4>\n

\n\t\t\n\t\tcarmen.gomez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Joan-Miquel-Nolla-Sol\u00e9\"\n

\n\t\tNolla Sole, Joan Miquel\n\t<\/h4>\n

\n\t\t\n\t\tjnolla@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Diego-Benavent-Nu\u00f1ez\"\n

\n\t\tBenavent Nu\u00f1ez, Diego\n\t<\/h4>\n\t\t\t\t\"Xavier-Juanola-Roura2\"\n

\n\t\tJuanola Roura, Xavier\n\t<\/h4>\n

\n\t\t\n\t\txjuanola@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tNarv\u00e1ez Garcia, Jose Antonio\n\t<\/h4>\n

\n\t\t\n\t\tjnarvaezg@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tBerbel Arcobe, Laura \n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\t@5Romera55\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t